Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38592091/
Atherosclerotic cardiovascular disease (ASCVD) represents a major global health challenge, significantly contributing to mortality rates. This chronic inflammatory condition affecting blood vessels is intricately linked to hypercholesterolemia, with elevated levels...
Atherosclerotic cardiovascular disease, driven by hypercholesterolemia, benefits from lipid-lowering therapies. Novel agents like PCSK9 inhibitors and bempedoic acid enhance LDL-C management, addressing statin limitations and advancing cardiovascular risk reduction strategies.
Share
Characteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39275243/
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD). During pregnancy, physiological changes elevate cholesterol and triglyceride levels to support fetal development, which can exacerbate pre-existing conditions and...
Dyslipidemia during pregnancy increases ASCVD risk and complications. Management, including dietary adjustments and selective pharmacological interventions, requires a personalized, multidisciplinary approach to balance maternal and fetal health, especially in inherited dyslipidemia.
Share
Therapeutic potential of adiponectin in prediabetes: strategies, challenges, and future directions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38250316/
Adiponectin, an adipose-derived hormone, plays a pivotal role in glucose regulation and lipid metabolism, with a decrease in circulating adiponectin levels being linked to insulin resistance and prediabetes. This review...
This review explores adiponectin's role in glucose regulation, insulin sensitivity, and lipid metabolism, highlighting strategies to boost its levels for managing prediabetes, and addressing challenges in clinical translation.
Share
Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38642715/
Alzheimer's and Parkinson's diseases are two of the most frequent neurological diseases. The clinical features of AD are memory decline and cognitive dysfunction, while PD mainly manifests as motor dysfunction...
Dysregulated lipid metabolism exacerbates Alzheimer's and Parkinson's diseases through various mechanisms, with emerging lipid-targeting therapies, like PPAR agonists and ApoE monoclonal antibodies, offering potential for treatment and prevention.
Share
Lipid metabolism disorder in diabetic kidney disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38742197/
Diabetic kidney disease (DKD), a significant complication associated with diabetes mellitus, presents limited treatment options. The progression of DKD is marked by substantial lipid disturbances, including alterations in triglycerides, cholesterol,...
This research investigates the connection between lipid metabolism disturbances and diabetic kidney disease (DKD), highlighting mechanisms like ferroptosis, lipophagy, and immune modulation, offering new therapeutic pathways for DKD management.
Share